← Back to Search

Tyrosine Kinase Inhibitor

X4P-001 for Renal Cell Carcinoma

Phase 1 & 2

Waitlist Available

Research Sponsored by X4 Pharmaceuticals

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 80 weeks, from time of enrollment through study completion or early termination

Awards & highlights

Study Summary

This trial will test the safety and effectiveness of a new drug, X4P-001, for treating advanced renal cell carcinoma.

Eligible Conditions

Renal Cell Carcinoma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 80 weeks, from time of enrollment through study completion or early termination

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 80 weeks, from time of enrollment through study completion or early termination

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 80 weeks, from time of enrollment through study completion or early termination for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Incidence of Treatment-Emergent Adverse Events (Safety and tolerability)

Secondary outcome measures

Area Under the Curve (AUC)

Disease Control Rate

Maximum Plasma Concentration (Cmax)

+3 more

Trial Design

3Treatment groups

Experimental Treatment

Group I: Part CExperimental Treatment1 Intervention

X4P-001 monotherapy

Group II: Part BExperimental Treatment2 Interventions

Randomized assignment to one of two regimens: X4P-001 at the Part A maximum tolerated dose (MTD), in combination with axitinib X4P-001 at 0.5x Part A MTD, in combination with axitinib

Group III: Part AExperimental Treatment2 Interventions

X4P-001 + axitinib dose escalation

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

X4P-001

2016

Completed Phase 2

~100

Axitinib

FDA approved

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

X4 PharmaceuticalsLead Sponsor

9 Previous Clinical Trials

288 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Recent research and studies

clinicaltrials.govStudy

Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma

2016. "Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02667886.

~8 spots leftby Apr 2025

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.